Conference
COST-EFFECTIVENESS ANALYSIS OF DUPILUMAB, MEPOLIZUMAB AND BENRALIZUMAB FOR SEVERE EOSINOPHILIC ASTHMA WITH BLOOD EOSINOPHIL COUNT $300 CELLS/MCL IN THE BRAZILIAN PRIVATE HEALTHCARE PERSPECTIVE
Authors
Taminato A; Barbosa A; Magro FJB; Federico P; Prioli RNT; Goldflus S; Migliavaca CB; Falavigna M
Volume
25
Pagination
pp. S54-S54
Publisher
ELSEVIER SCIENCE INC
Publication Date
December 1, 2022
Conference proceedings
VALUE IN HEALTH
Issue
12
ISSN
1098-3015